Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. [electronic resource]
Producer: 20050614Description: 1048-53 p. digitalISSN:- 1549-4713
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Choroidal Neovascularization -- diagnosis
- Female
- Fluorescein Angiography
- Humans
- Immunoglobulin Fragments -- immunology
- Injections
- Macular Degeneration -- complications
- Male
- Maximum Tolerated Dose
- Middle Aged
- Prospective Studies
- Ranibizumab
- Safety
- Vascular Endothelial Growth Factor A -- immunology
- Visual Acuity
- Vitreous Body -- drug effects
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.